INFOGRAPHIC: PCSK9 inhibitors alirocumab and evolocumab side-by-side
This article was originally published in Scrip
Clinical trial results to date for the PCSK9 inhibitors evolocumab from Amgen and alirocumab from Sanofi and Regeneron Pharmaceuticals have been quite similar in patients with hypercholesterolemia, or high cholesterol, across several studies even though no two study designs are exactly alike.
You may also be interested in...
Private Company Edition: Arvelle, insitro, AbCellera and the University of Michigan have something in common – they each attracted more than $100m in venture capital investment.
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.